BGI Genomics and genomiQa sign a services agreement for whole genome sequencing on BGI’s DNBseqTM sequencing technology platform; Unlocking the power of whole genome analysis for cancer patients across Asia.
“We have been working with BGI on a number of research projects and validation studies to reach this exciting milestone. More importantly we will start to help patients who have only had access to comprehensive panels, where up to 38%1 of breast cancer patients may not have received the best treatment options, as actionable information was not available’’, said Colin Albert – CEO genomiQa.
Dr Bicheng Yang, Director of BGI Australia said, “We are really pleased with the growth of our sequencing services on DNBseqTM technology platform, and the opportunity to support innovative companies like genomiQa.
By offering competitive pricing for our sequencing services BGI is helping genomiQa unlock whole genome analysis for patients. By working together with genomiQa, researchers and physicians can use whole genome analysis to unlock potential new treatments and support the best patient outcomes similar to the “Immunotherapy Outcomes Predication” project we are working together on2”.
John Pearson, genomiQa’s Co-Founder and Chief Technology Officer said, “We have validated our pipeline on multiple BGI sequencing platforms, culminating in today’s signing of the services agreement.
We are continually striving for the highest possible level of quality in our services and we use our NGSCheckTM quality control software, which assess the quality of all sequencing data that enters our analysis pipeline.”
“By integrating BGI’s proprietary DNBseqTM sequencing technology and genomiQa’s whole genome analysis pipelines, we are looking forward to offering the powerful and accessible solutions for improving cancer treatments and clinical outcomes. ” said Yonggang Zhao, the Business Director of BGI Genomics.
genomiQa also intends to use BGI’s facility in Australia, once it has completed the ISO 15189 accreditation process, which is anticipated within the next 12 months.
Colin Albert – CEO – genomiQa, +61429 512 888, email@example.com
Bicheng Yang, Director BGI Australia, +61451861227, firstname.lastname@example.org
- BGI Genomics, a subsidiary of BGI, provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners.
- BGI’s mission is to leverage its genomics expertise in order to advance life science research and improve human health for the benefit of mankind.
- Numerous scientific partners, healthcare providers and pharmaceutical companies have come to rely on BGI’s world leading bio-informatics research and development, large scale computing infrastructure for data output and storage, and proprietary sequencing platforms.
- BGI is headquartered in Shenzhen, China, with branches and medical laboratories in major cities including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou. BGI also has offices and laboratories located in Europe, North America and the Asia Pacific region.
- BGI currently operates in more than 100 countries and regions and works with more than 3000 medical institutions and more than 300 hospitals.
- DNBseq™ technology is a proprietary sequencing technology originally developed by Silicon Valley based Complete Genomics, which was acquired by BGI in 2013. DNBseq™ sequencing technology is powered by PCR-free Rolling Circle Replication, combinatorial Probe-Anchor Synthesis (cPAS) and DNA Nanoballs (DNB) technology.
- genomiQa is a start-up company out of the QIMR Berghofer Medical Research Institute, which provides computational pipeline services to analyse whole genome data, DNA/RNA. The high-quality genomic pipeline was developed by founders Dr Nic Waddell and John Pearson and offered clinicians and companies high-quality analysis of genomic data to inform health care decisions.
- CapeXLTM – analyses all genomes, not limited to comprehensive panels, and reports on Tumour Mutational Burden (TMB) and possible treatment options that are: indicated, related to the genomic drivers discovered or currently being studied in clinical trials
- NGSCheckTM will be available for use by pathologists and other users of NGS machines to assess the NGS output quality. Improving quality for better patient outcomes.
- 138% improvement – data on file; Panel: 47.5%, Whole Exome Analysis: 58% and Whole Genome Analysis: 86%
2Immunotherapy Outcomes Project
- genomiQa and BGI are incredibly proud to be partnering with the teams from Max Kelsen, Royal Brisbane and Women’s Hospital (RBWH) & QIMR Berghofer Medical Research Institute.
- The partnership received $2.6 million from the Federal Government’s CRC-P Program, and has attracted an additional $6.4 million of cash and in kind contributions from industry partners.
- This project will firmly establish the role of whole genome analysis and artificial intelligence to help predict the response of immunotherapy for the treatment of cancer as well as supporting personalised medicine and physician-led treatment decisions